TCR Repertoire and Transcriptional Signatures of Circulating Tumour‐associated T Cells Facilitate Effective Non‐invasive Cancer Detection
Fansen Ji,Lin Chen,Zhizhuo Chen,Bin Luo,Yongwang Wang,Xun Lan
DOI: https://doi.org/10.1002/ctm2.853
IF: 8.554
2022-01-01
Clinical and Translational Medicine
Abstract:Clinical and Translational MedicineVolume 12, Issue 9 e853 LETTER TO THE EDITOROpen Access TCR repertoire and transcriptional signatures of circulating tumour-associated T cells facilitate effective non-invasive cancer detection Fansen Ji, Fansen Ji orcid.org/0000-0002-4220-0786 Tsinghua-Peking Center for Life Sciences, MOE Key Laboratory of Tsinghua University, Beijing, China School of Medicine, Tsinghua University, Beijing, ChinaSearch for more papers by this authorLin Chen, Lin Chen School of Medicine, Tsinghua University, Beijing, China General Surgery Department, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, ChinaSearch for more papers by this authorZhizhuo Chen, Zhizhuo Chen School of Life Science, Tsinghua University, Beijing, ChinaSearch for more papers by this authorBin Luo, Corresponding Author Bin Luo luobin@mail.tsinghua.edu.cn General Surgery Department, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China Correspondence Xun Lan, School of Medicine, Tsinghua University, Haidian District, Beijing 100084, China. Email: xlan@tsinghua.edu.cn Bin Luo, Beijing Tsinghua Changgung Hospital, Room 431, Building 3, 168 Litang Road, Changping District, Beijing 102218, China. Email: luobin@mail.tsinghua.edu.cn Yongwang Wang, Department of Anesthesiology, Affiliated Hospital of Guilin Medical University, No.15 Lequn Road, Xiufeng District, Guilin 541001, China. Email: wangyongwang81@126.comSearch for more papers by this authorYongwang Wang, Corresponding Author Yongwang Wang wangyongwang81@126.com Department of Anesthesiology, Affiliated Hospital of Guilin Medical University, Guilin, China Correspondence Xun Lan, School of Medicine, Tsinghua University, Haidian District, Beijing 100084, China. Email: xlan@tsinghua.edu.cn Bin Luo, Beijing Tsinghua Changgung Hospital, Room 431, Building 3, 168 Litang Road, Changping District, Beijing 102218, China. Email: luobin@mail.tsinghua.edu.cn Yongwang Wang, Department of Anesthesiology, Affiliated Hospital of Guilin Medical University, No.15 Lequn Road, Xiufeng District, Guilin 541001, China. Email: wangyongwang81@126.comSearch for more papers by this authorXun Lan, Corresponding Author Xun Lan xlan@tsinghua.edu.cn Tsinghua-Peking Center for Life Sciences, MOE Key Laboratory of Tsinghua University, Beijing, China School of Medicine, Tsinghua University, Beijing, China Correspondence Xun Lan, School of Medicine, Tsinghua University, Haidian District, Beijing 100084, China. Email: xlan@tsinghua.edu.cn Bin Luo, Beijing Tsinghua Changgung Hospital, Room 431, Building 3, 168 Litang Road, Changping District, Beijing 102218, China. Email: luobin@mail.tsinghua.edu.cn Yongwang Wang, Department of Anesthesiology, Affiliated Hospital of Guilin Medical University, No.15 Lequn Road, Xiufeng District, Guilin 541001, China. Email: wangyongwang81@126.comSearch for more papers by this author Fansen Ji, Fansen Ji orcid.org/0000-0002-4220-0786 Tsinghua-Peking Center for Life Sciences, MOE Key Laboratory of Tsinghua University, Beijing, China School of Medicine, Tsinghua University, Beijing, ChinaSearch for more papers by this authorLin Chen, Lin Chen School of Medicine, Tsinghua University, Beijing, China General Surgery Department, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, ChinaSearch for more papers by this authorZhizhuo Chen, Zhizhuo Chen School of Life Science, Tsinghua University, Beijing, ChinaSearch for more papers by this authorBin Luo, Corresponding Author Bin Luo luobin@mail.tsinghua.edu.cn General Surgery Department, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China Correspondence Xun Lan, School of Medicine, Tsinghua University, Haidian District, Beijing 100084, China. Email: xlan@tsinghua.edu.cn Bin Luo, Beijing Tsinghua Changgung Hospital, Room 431, Building 3, 168 Litang Road, Changping District, Beijing 102218, China. Email: luobin@mail.tsinghua.edu.cn Yongwang Wang, Department of Anesthesiology, Affiliated Hospital of Guilin Medical University, No.15 Lequn Road, Xiufeng District, Guilin 541001, China. Email: wangyongwang81@126.comSearch for more papers by this authorYongwang Wang, Corresponding Author Yongwang Wang wangyongwang81@126.com Department of Anesthesiology, Affiliated Hospital of Guilin Medical University, Guilin, China Correspondence Xun Lan, School of Medicine, Tsinghua University, Haidian District, Beijing 100084, China. Email: xlan@tsinghua.edu.cn Bin Luo, Beijing Tsinghua Changgung Hospital, Room 431, Building 3, 168 Litang Road, Changping District, Beijing 102218, China. Email: luobin@mail.tsinghua.edu.cn Yongwang Wang, Department of Anesthesiology, Affiliated Hospital of Guilin Medical University, No.15 Lequn Road, Xiufeng District, Guilin 541001, China. Email: wangyongwang81@126.comSearch for more papers by this authorXun Lan, Corresponding Author Xun Lan xlan@tsinghua.edu.cn Tsinghua-Peking Center for Life Sciences, MOE Key Laboratory of Tsinghua University, Beijing, China School of Medicine, Tsinghua University, Beijing, China Correspondence Xun Lan, School of Medicine, Tsinghua University, Haidian District, Beijing 100084, China. Email: xlan@tsinghua.edu.cn Bin Luo, Beijing Tsinghua Changgung Hospital, Room 431, Building 3, 168 Litang Road, Changping District, Beijing 102218, China. Email: luobin@mail.tsinghua.edu.cn Yongwang Wang, Department of Anesthesiology, Affiliated Hospital of Guilin Medical University, No.15 Lequn Road, Xiufeng District, Guilin 541001, China. Email: wangyongwang81@126.comSearch for more papers by this author First published: 22 September 2022 https://doi.org/10.1002/ctm2.853Citations: 1 Fansen Ji and Lin Chen contributed equally to this study. AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat The concept of precision medicine in oncology has dramatically transformed the clinical application of tumour screening, which makes the malignancies more curable if diagnosed early. Traditional serological tumour biomarkers like α-fetoprotein, prostate-specific antigens, carcinoembryonic antigens, CA19–9 and CA125 have been widely investigated in clinic, but the specificity has not reached a satisfactory stage for population level.1-3 Novel technologies utilizing tumour-derived signals from blood non-invasively provide a new tumour diagnostic strategy called liquid biopsy over the past decades.3-5 Several peripheral biomarkers such as cell-free DNA (cfDNA)6-8 especially circulating tumour DNA (ctDNA),9 circulating tumour cells (CTCs),10, 11 circulating micro-RNAs,12, 13 tumour-derived exosomes14 and cancer cell metabolites15 achieved great progress and showed huge prospects in tumour screening. However, these methods are all derived from the modality of tumour and often need predefined panels or biomarkers for diagnosis, which may be non-specific and subjective due to the heterogeneous properties of tumour. The feasibility of using tumour-associated T cell response involved in tumour initiation and development, as a supplementary diagnosis choice has not been explored widely.16, 17 Until recently, tumour-infiltrated T lymphocytes (TILs) were considered to be beneficial tumour-specific T cells.18 But due to the complex interaction of different immune components mediated by chemokines or cytokines within the tumour microenvironment (TME), the majority of passively expanding TILs cannot recognize tumour-specific antigens (TSAs) and are thus believed to be bystander T cells.19-21 These bystander T cells may dilute tumour-specific signals and make the identification of TSAs-specific T cells challenging.22-24 Programmed cell death protein 1 (PD-1) is suggested to be a biomarker for tumour-specific CD8+ T cells both in TILs and in peripheral blood mononuclear cells (PBMCs),22, 25-27 but the efficacy needs to be further validated in practical applications.21, 28, 29 Tracking the general immunophenotype of T lymphocytes when they encounter antigens and enrichment of tumour-associated T cells over a pool of irrelevant signals during tumour development reflects the overall immune status of patients and offers opportunities for cancer prevention and therapy.30 Next generation sequencing (NGS)-based T cell receptor (TCR) repertoire quantification has provided methods for TSA recognition and now is extensively used in the identification of tumour-reactive T lymphocytes.19, 31-34 The past few years have witnessed a series of studies utilizing T or B-cell repertoire to pinpoint disease-associated signatures, and evidences have demonstrated the diagnostic potential of TCR repertoire in autoimmune diseases,35 infectious diseases36, 37 and even cancer.38-42 Sustained neoantigen stimulation during tumour cell development impels TCR to shift towards a tumour-specific distribution and to exhibit different amino acids motifs than those in healthy cells.38, 43 Under physiological conditions, naïve T cells maturing in the thymus will flow through peripheral blood or lymphatic vessels and migrate through high endothelial venules into secondary lymphoid organs where they encounter potential tumour antigens.44, 45 T cell trafficking and circulation theoretically enable these tumour-specific T cells to be detectable both in tumour sites and peripheral blood. T lymphocytes circulating among PBMCs that paired with TILs residing in tumour tissues have been suggested to be highly correlated with T cell-induced cytotoxicity and to indicate enrichment of tumour reactive signals.22, 46-51 Elucidating the connection between anti-tumour T cells in the periphery and those in the TME22, 25, 44, 45, 52 may provide clues to design novel approaches for non-invasive tumour screening. Assessing overlapping TCRs between PBMCs and TILs and considering them tumour-specific predictors will not only help us comprehensively study T cell circulation and migration but will alleviate the deficiencies caused by using the TIL population only, which is enriched with bystander T cells. In this study, we defined a group of circulating T lymphocytes in PBMCs that shared TCRs with TILs as tumour-associated T cells (TATs). Using the CDR3 sequences of TATs with those in healthy TCRs as input data, we trained a binary model to distinguish TATs from healthy clones. Applying this model on several independent clinical datasets, we acquired the number of TAT sequences in PBMCs for each individual. We then designed a TCR repertoire risk score (TRRS) as the number of TATs our model predicted in the PBMCs divided by the number of detected healthy TCRs from healthy individuals. We demonstrated that the TRRS separated tumour patients from healthy donors effectively. Next, we characterized the transcriptional signatures of TATs in the PBMC populations using multiple single cell RNA sequencing (scRNA-seq) coupled with TCR sequencing datasets and found that T cell activation pathway was significantly up-regulated in TATs. Combining the TCR repertoire and transcriptional signatures of TATs,53 we developed an integrated framework for non-invasive tumour screening using only PBMC samples. Furthermore, we performed bulk TCR and RNA sequencing of PBMC samples from 11 tumour patients and six healthy donors and validated the performance of this tumour screening strategy with these data and another independent cohort. Our study proves the principle of using TATs as an alternative non-invasive tumour screening biomarker and broadens the liquid biopsy application from the view of the immune landscape. T cells with identical TCR sequences are thought to be derived from a single naïve T cell, which migrates and circulates among different tissue types and may undergo a functional state transition upon antigen stimulation.54 Based on the TCR-sharing relationship of TILs and PBMCs, we first divided TCR clonotypes in PBMCs and TILs into four different compartments (Figure 1A). TCR clonotypes of PBMCs that are identical to those of TILs are called PBMCs_Shared compartment, while clonotypes of TILs that are identical to those of PBMCs are called TILs_Shared compartment. These two compartments have the same TCR clonotypes, but their tissue sources distinguish them. Due to different tissue environment, the frequency of each clonotype and the degree of clonality between the two compartments may differ. Therefore, we specifically named the T cells among PBMCs that share TCRs with TILs as circulating Tumor Associated T cells (cTATs). In contrast, the TCR clonotypes that are unique to TILs are in the TILs_only compartment, and the TCR clonotypes observed only in PBMCs are in the PBMCs_Only compartment. We believe that the PBMCs_Only compartment most likely represents naïve, effector or memory T cells in periphery that are not related to the tumour immune response. T cells in the TILs_Only compartment may largely represent tissue-resident T cells, which are not in the set of T lymphocytes prevalent in circulation. It should be noted that due to the technical limitation of TCR repertoire sequencing, both TILs_Only and PBMCs_Only compartments actually contain a proportion of overlapped clonotypes that cannot be detected sensitively at present. FIGURE 1Open in figure viewerPowerPoint T cell receptor repertoire (TCR) sharing relationship between the tumour microenvironment, and the periphery defines four different compartments. (A) Schematic overview of TCR sharing relationship between PBMCs and tumour-infiltrated T lymphocytes (TILs) and the definition of the four TCR compartments. (B) Length distribution of the CDR3 beta chains within the four different TCR compartments. (C) V gene usage of the CDR3 beta chains in different TCR compartments. (D) Proportion of shared TCRs among different tissue types (TILs or PBMCs) at both sequence level and clone level. (E–F) The indices of clonality and Gini coefficient among different TCR compartments and that from healthy donor PBMCs samples. (G–H) Correlation between the overall clonality/Gini coefficient and the proportion of shared TCRs in PBMCs and TILs This framework allowed us to use TCR sequences as molecular barcodes to track and analyse the function of TATs among TILs and PBMCs. We collected a series of TCR CDR3 β chain sequencing data of paired PBMCs and tumour tissues from the same patient (Table S1) and assigned each T cell clonotype to one of the four compartments using the aforementioned definitions. After removing non-functional TCRs, we found that, among the different compartments, most (91%) of the TCR CDR3 sequences were 12∼17 amino acids in length (Figure 1B). In addition, the CDR3 sequence length distribution in the TILs resembles that in the PBMCs, indicating that there is no CDR3 length difference between these cells in the two different tissue types. Next, because TCR beta chain variable (TCRBV) genes contributed the most diversity to CDR3 sequences, we analysed the TCRBV gene usage in the different compartments. We found that TRBV genes, such as TRBV06/14/15/20/25, are expressed more frequently in the shared compartments than in the non-shared compartments43 (Figure 1C), which suggests that the antigen specificities of TCRs may differ between these compartments. In the following analysis, subsets with CDR3 sequences of 12∼17 amino acids were analysed, and TCRs with excessively long or short CDR3 regions were removed. To estimate the degree of TCR sequence overlap in PBMCs and TILs, we calculated the relative proportion of TCRs shared by both TILs and PBMCs in each sample. We found that the proportion of TCRs in the TILs_Shared compartment (approximately 22.56%, 95% confidence interval (CI): 12.82%–37.51%) was significantly higher (p < 1e−4) than the proportion in the cTATs of the PBMC population (approximately 3.08%, 95% CI: .64%–5.15%, Figure 1D), which indicated that TILs show higher shared TCR enrichment than PBMCs possibly due to the close interaction of T lymphocytes with TSAs in the TME. This result is consistent both at the TCR clone and TCR sequence level (Figure 1D). The same analysis based on single-cell TCR sequencing (TCR-seq) data showed no significant differences (p > .05) in the proportion of shared TCRs at either the clone or sequence level, possibly due to the limited number of cells captured in single cell TCR-seq datasets, and many shared clones might be labelled as not shared (Figure S1A). TCR sequences with a high degree of similarity and clonal expansion are more likely to recognize TSAs effectively. We found the indices of clonality and Gini coefficient in the PBMCs_Shared compartment were higher (p < 1e−4) than those in PBMCs_Only compartment (Figure 1E,F). The same trend was also observed in the PBMC population when single cell TCR-seq data were analysed (Figure S1B). These results indicate that TATs are more likely to undergo clonal expansion and to represent functional tumour-reactive T cells. Adding a healthy donor cohort PBMC dataset36 as the control (see Methods), we found that the clonality and Gini coefficient of the healthy samples were lower (p < 1e−3) than those of the shared compartments and higher than those of the tissue-only compartments (Figure 1E,F), possibly due to the baseline immune activity that developed against common antigens in the surrounding environments, such as influenza virus or human cytomegalovirus (HCMV). Our results suggest T cell clones in the shared compartment are more likely to be tumour reactive and are different from those induced by non-tumour antigens commonly present in healthy individuals. Moreover, we found that the proportion of TATs in blood, which is observable only when tumour tissue is sequenced, was highly correlated with the overall T cell clonality and Gini coefficient of PBMCs, which were obtained non-invasively; however, such correlation was not observed in TILs (Figure 1G,H). These results highlight the potential of using the T cell clonality and Gini coefficient of PBMCs as indicators of cancer development. TATs among PBMCs are more likely to reflect the clonal expansion of T lymphocytes in periphery, and a higher degree of shared TCR clones among PBMCs may indicate that more neoantigen-specific T cells pre-exist in the PBMCs. It has been reported that a greater degree of PBMC-TIL TCR repertoire overlap indicates an improved immune response and is associated with better clinical outcome of immunotherapy.42, 47, 49, 55 We believe that this compartment largely represents tumour reactive T cells and may serve as a biomarker to distinguish blood samples of cancer patients from those of healthy individuals. In this study, we sought to build a deep learning binary classifier to predict tumour-reactive TCR sequences. To construct a training dataset for the model, we first downloaded a publicly available TCR sequencing data obtained from PBMC samples of healthy individuals36 as the control dataset and only used data from HCMV-negative individuals to exclude potential tumour-irrelevant immune signals. Two datasets of healthy cohorts were included in the analysis, and we named these sets Healthy351 and Healthy69 according to the number of samples after filtering. Since the Healthy351 included more healthy donors and TCRs (more than 30 million), we considered the TCRs in this cohort to be a healthy TCR pool and used these data to identify the TCR sequences that overlapped with those in the PBMCs from cancer patients. Then, we extracted TAT TCRs in PBMC samples from TIL-PBMC-paired TCR sequencing datasets described above and filtered TCRs that were also detected in Healthy351. We labelled the remaining TAT TCRs as positive samples and the TCRs in Healthy351 as negative samples. The schematic workflow and experimental design are summarized in Figure S2A. Deep convolutional neural networks (CNNs) generally performed better in TCR pattern recognition studies 56-58; therefore, we encoded the CDR3 beta chain using the one-hot encoding method and built a three-layer CNN to distinguish the TCRs of TATs from those of healthy individuals. The output of the CNN is the probability of each input TCR sequence being the TCR of a TAT. Next, we generated a TRRS for each PBMC sample summarizing the number of TATs our model had predicted in PBMC relative to the number of healthy TCRs that had been detected in the Healthy351 dataset. We evaluated the performance of the TRRS for non-invasive cancer detection with several independent PBMC datasets obtained from cancer patients using Healthy69 as negative samples. The detailed illustration of model construction is presented in the Methods. We first selected the same number of negative TCRs as that of TATs and used five-fold cross validation to test the generalization ability of our CNN model. Considering the heterogeneity of cancer patients, the data were split at the patient level rather than at the TCR sequence level to ensure that the model did not learn sample-specific confounding effects. Both the receiver operating characteristic curve (ROC) curve and precision-recall curve (PRC) (Figure 2A,B) showed the model performed modestly well in differentiating TCRs of TATs from TCRs of healthy samples (ROC: .699–.706, PRC: .446–.787) and are not influenced by human leukocyte antigen (HLA) haplotypes (Methods, Figure S2B,C). Because we randomly split patients into the training and test dataset and high variation in the number of TATs exists in different patients, the PRC shows high variability across the different iterations of random splits. The final model was trained and validated using the entire data, and as the number of training epochs increased to about 60, the loss and accuracy had reached a plateau (Figure 2C). Further inspection of the prediction probability distribution of different CDR3 length indicated a significant difference between the TCRs of TATs and those of healthy samples (Figure 2D). FIGURE 2Open in figure viewerPowerPoint Development of binary model to predict tumour-associated T cells (TATs) in the peripheral blood and using the T cell receptor repertoire (TCR) repertoire risk score (TRRS) to distinguish tumour patients from healthy individuals. (A–B) Model ROC and precision-recall curve (PRC) by five-fold cross validation. (C) The model loss/accuracy changes at different epochs. (D) The model prediction probability score for different CDR3 lengths among tumoural and non-tumoural TCRs. (E) The TCR repertoire risk score (TRRS) in PBMC samples among tumour patients from different cancer types, healthy individuals from the Healthy69 cohort and human cytomegalovirus (HCMV) positive samples. (F) The ROC plot of TRRS in differentiating tumour patients from healthy donors at a given threshold of .66. (G–H) The indices of clonality and Gini coefficient between TRRS-high group and TRRS-low group. (I–J) The amino acid motif between TAT probability high group (top panel) and low group (bottom panel) Then, to test whether the TAT prediction probability of our model can be used as a biomarker for differentiating tumour patients from healthy donors, we obtained seven independent datasets55, 59-64 containing PBMC TCR sequencing data of patients with different cancer types (Figure S2A). The Healthy69 cohort was used as the negative controls set. We used a TRRS (Methods) to estimate the degree of TAT enrichment in the PBMC population of each sample. Briefly, we counted the number of TATs our model has predicted and then divided it by the number of healthy TCRs in PBMCs that overlapped with the Healthy351 pool. At a threshold above .66, the TRRS can differentiate PBMC samples of normal individuals from those of patients with various cancer types effectively (Figure 2E,F), indicating the feasibility of using TRRS of TATs for non-invasive tumour screening. We found that our result is robust by setting the threshold at different levels (Figure S3A–F). To provide evidence that the prediction of our model was not simply a generic active cell-mediated immune response, we introduced an experimentally validated HCMV positive cohort with TCR-seq data from their PBMC samples (Table S1). We calculated the TRRS for these individuals and compared them with that of the cancer patients. We show that the TRRS of HCMV positive cohort is lower than that of the cancer patients, indicating our model is able to distinguish individuals with cancer from those with infectious diseases. Based on the TRRS, we divided the samples in the independent validation cohort into high-risk and low-risk group separated at the 50% quantile. We found that the clonality and Gini coefficient in the high-risk group were significantly higher (p < 1e−3) than those in the low-risk group (Figure 2G,H), implying that the TCRs in the high-risk group were associated with more clonal expansion and active immune functions. In addition, we analysed sequence motif enrichment in TCRs with the top 25% and bottom 25% probabilities of being a TAT (Figure 2I,J). We found that CDR3 sequences in the high probability group showed an enrichment of serine in the second position, while those in the low probability group tended to have an alanine in this position. Sending publicly available databases of virus/bacterial TCR sequences into the prediction model shows that CDR3 sequences among different lengths tended to have an alanine in the second position, which indicates that features specifically associated with the TCR of clonally expanded TATs are not enriched in virus/bacteria TCRs (Figure S3L). In summary, we used TCR sequences from TATs and healthy donors to build a binary predictive CNN model and designed a TRRS based on the model prediction for effective non-invasive cancer screening with PBMCs. Single-cell-RNA-multiplexed-TCR-sequencing (scRNA-TCR-seq) technology makes it possible to not only trace the TCR clone sharing relationship between tumour and paired PBMCs samples, but also quantify the transcriptomics patterns at the single cell level.43, 54, 65-69 We performed a comprehensive literature review and obtained 14 high-quality scRNA-TCR-seq datasets that met our criteria (Table S2). We found no significant difference (p > .05) in the CD4+/ CD8+ ratio between PBMCs from cancer patients and healthy donors (Figure 3A), implying that the relative ratio of CD4+ and CD8+ T cells remains unchanged after tumour initiation, in contrast to the ratio in patients with acute infection, which is usually lower than that in uninfected healthy samples.70-72 However, the proportion of clonal T cells (clone frequency > 2) was higher (p < 1e−3) in tumour patients than in healthy donors (Figure S4A), indicating a higher clonal expansion of T cells in cancer patients. Moreover, we found that the CD4+/ CD8+ ratio was significantly lower in TATs than in non-clonal T cells (clone frequency = 1) in patient PBMCs (Figure 3B), suggesting that the expansion of CD8+ T cell is greater than that of the CD4+ cells upon tumour antigen stimulation. FIGURE 3Open in figure viewerPowerPoint Transcriptional signature gene analysis using single cell data shows T cell activation is involved in the tumour-associated T cells (TATs). (A) CD4+/ CD8+ T cell relative ratio in PBMCs between tumour and healthy samples calculated by single cell data. (B) CD4+/ CD8+ T cell relative ratio between TATs and non-clonal T cells in PBMCs. (C) The proportion of TATs in tumour and healthy-specific clusters (in which tumour patients or healthy donors derived T cells occupy more than 70%, see Methods) by TCR functional landscape estimation supervised with scRNA-seq analysis (TESSA) clustering analysis. (D) T cell subtype distribution in different T cell receptor repertoire (TCR) compartments. (E) Heatmap shows differentially expressed genes between TATs and non-clonal T cells. (F) Gene Ontology (GO) analysis of TAT differentially expressed genes Next, to provide further evidence that TATs represent tumour-specific T cells among PBMCs, we performed clustering analysis utilizing both single-cell RNA and TCR information of T cells among tumour and healthy donor PBMCs by the TCR functional landscape estimation supervised with scRNA-seq analysis (TESSA)73 algorithm. We found that tumour-specific clusters had a higher proportion of TATs than normal specific clusters (p < 1e−4) in nearly all the 14 datasets (Figure 3C, Methods), indicating that TATs in the blood of patients with various types of cancer are tumour specific and dissimilar to T cells in the blood of healthy donors. To integrate datasets from various sources, we used a label transfer method74 by taking one clear cell renal cell carcinoma (ccRCC) dataset75 as the reference due to its detailed cell type annotation information. Then we projected the cells from other datasets onto the reference map to transfer the cell type annotation. We found that most T cells in the non-clonal group were CD4+ naïve/proliferating/effector T cells, while most TATs were CD8+ NK-like/effector T cells (Figure 3D). These results demonstrated that TATs are mostly activated CD8+ T cells and may exert cytotoxic functions upon tumour stimulation. To further explore transcriptional signatures of TATs among PBMCs, we performed differential gene expression analysis between CD8+ TATs and non-clonal T cells in each dataset. To prevent potential batch effects caused by using different data sources and guarantee a robust analysis, genes that were
What problem does this paper attempt to address?
-
Abstract 2295: Circulating T cell receptor repertoire analysis improves cancer early detection
Yilong Li,Michelle Nahas,Dennis Stephens,Kate Froburg,Emma Hintz,Devin Champagne,Amaneet Lochab,Markus Brown,Jesse Abhyankar,Jasper Braun,Michelle Dinh,María Antonia Fortuño,María-del-Mar Ocon,Andrea Pasquier,Inés María Luque,Christopher W. Seder,Jeffrey A. Borgia,Luis Miguel Seijo,Luis M. Montuenga,Roman Yelensky
DOI: https://doi.org/10.1158/1538-7445.am2024-2295
IF: 11.2
2024-03-22
Cancer Research
Abstract:Abstract Background: Cancer screening by liquid biopsy promises to detect cancer early when it can be cured. However, current liquid biopsy approaches based on circulating tumor DNA (ctDNA) detect only a minority of early-stage cancers, because these tumors shed little ctDNA and plasma sample volume is limited. For liquid biopsy to realize its potential for the early detection of cancer, sensitivity for the earliest stage disease must be improved. Methods: We set out to improve sensitivity of liquid biopsy for cancer early detection by exploiting tumor recognition by T cells through sequencing of the circulating T cell receptor repertoire. Using gDNA extracted from blood buffy coats, we studied a cohort of 451 lung cancer patients (86% with stage I disease) and 525 subjects without cancer, enriched for older individuals with a history of smoking. We performed genomic DNA TCR beta chain sequencing to yield a median of 81,088 TCR clonotypes in cancer patients and 112,588 clonotypes in non-cancer controls. We built a TCR sequence similarity nearest neighbor graph to cluster >68M distinct TCR clonotypes into TCR repertoire functional units (RFUs). The TCR frequencies of RFUs were tested for association with cancer status and significantly associated RFUs were combined using a support vector machine model into a TCR RFU cancer score. This model was evaluated by 10-fold cross-validation (CV) and compared to a ctDNA panel of 237 mutation hotspots in 154 lung cancer driver genes (IDTTM) and to a panel of 17 lung cancer related protein biomarkers (Olink®) in 87 subjects. Results: We identified 177 cancer-associated TCR RFUs at FDR≤0.10, including 83 RFUs that were enriched in cancer samples with a TCR count log2-fold change between 0.05 and 1.31, and 94 that were enriched in controls with a log2-fold change between 0.07 and 0.40. We observed 56 of the 83 cancer-enriched RFUs had decreasing TCR counts with increasing age across the cohort, coupled with higher counts in cancer patients relative to age-matched controls. The TCR RFU cancer score achieved a cross-validated ROC AUC of 0.69 for cancer status prediction, with the AUC for stage I cancers similar to that of stage II-IV (0.69 vs. 0.70). 44% of stage I cancers (test samples of each CV fold) were detected by the TCR model at a specificity of 80%. We saw a substantial gain in sensitivity for stage I cancer when TCR RFUs were added to ctDNA and proteins, with a ~15-20%-point increase seen at the 90% target specificity level typical for cancer screening tests. Likewise, sensitivity increased at the 99% specificity level used in multi-cancer early detection, with 35% of stage I lung cancers detected, which could not be achieved by any analyte alone. Conclusion: We demonstrate detection of a significant fraction of early lung cancer cases from blood by analyzing the circulating TCR repertoire and show that this signal is complementary to established analytes such as proteins and ctDNA. Citation Format: Yilong Li, Michelle Nahas, Dennis Stephens, Kate Froburg, Emma Hintz, Devin Champagne, Amaneet Lochab, Markus Brown, Jesse Abhyankar, Jasper Braun, Michelle Dinh, María Antonia Fortuño, María-del-Mar Ocon, Andrea Pasquier, Inés María Luque, Christopher W. Seder, Jeffrey A. Borgia, Luis Miguel Seijo, Luis M. Montuenga, Roman Yelensky. Circulating T cell receptor repertoire analysis improves cancer early detection [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2295.
oncology
-
Abstract 5595: Serial monitoring of circulating tumor cells and circulating tumor DNA in metastatic lobular breast cancer identifies intra-tumor heterogeneity and precision and immuno-oncology biomarkers of therapeutic importance
Andi K. Cani,Emily M. Dolce,Kevin Hu,Chia-Jen Liu,Elizabeth P. Darga,Dan Robinson,Yi-Mi Wu,Dafydd G. Thomas,Costanza Paoletti,Scott A. Tomlins,James M. Rae,Aaron M. Udager,Arul M. Chinnaiyan,Erin F. Cobain,Daniel F. Hayes
DOI: https://doi.org/10.1158/1538-7445.am2023-5595
IF: 11.2
2023-04-04
Cancer Research
Abstract:Abstract Precision and immuno-oncology clinical decisions are based on predictive biomarkers. Circulating biomarkers offer a minimally invasive approach to monitor intra-patient tumor heterogeneity and detect in real-time the clinically-relevant evolving clonal architecture. Although currently underutilized, single-cell DNA next generation sequencing of circulating tumor cells (CTC) is a particularly suitable method to complement tissue and circulating tumor DNA (ctDNA). Here we analyzed 113 individual CTC, 21 ctDNA, 15 white blood cells (WBC) samples and 15 tissue biopsies, from 15 CTC-positive lobular breast cancer patients. CTC were enriched with the CellSearch® system and isolated as single cells with the DEPArrayTM system. CTC, WBC, and ctDNA underwent scNGS with the Oncomine Comprehensive Assay covering ~500 genes and 1.1Mb of genomic space to detect mutations, copy number alterations, tumor mutation burden (TMB) and microsatellite instability (MSI). 99.1% of single cells and 95.2% of ctDNA samples were informative. Our CTC-based precision medicine reporting platform, MI-CTCSeq, detected CTC in 9 of 15 patients (60%) with FDA-approved actionable alterations including in the oncogenes PIK3CA and FGFR2 and HER2. 3 of these 9 (33%) harbored actionable alterations not shared between all 3 analyte types (tissue, CTC and ctDNA) including 3 actionable mutations found in CTC and ctDNA only, 1 in tissue and ctDNA only, and 1 in ctDNA only. Two of those ctDNA mutations were identified near the limit of detection and with a priori knowledge from tissue or CTC. Interestingly, 1 patient with plentiful CTC had no detectable ctDNA. Another patient’s tissue biopsy was inadequate for sequencing while both liquid biopsy analytes were abundant. 13 patients (87%) displayed intra-patient, inter-CTC genomic heterogeneity of driver mutations. 1 of 4 (25%) patients with CTC available in >1 timepoint displayed fluctuations in their CTC subclonal makeup between timepoints. Data from this patient’s 2 tissue biopsies, 4 ctDNA samples, and 27 individual CTC over 6 timepoints, combined to reveal in unprecedented detail inter-metastatic lesion and inter-CTC heterogeneity and evolution in response to endocrine, chemo and immunotherapy selective pressures. In a novel approach we show detection of single-cell CTC TMB and MSI. CTC TMB was highly concordant (R 0.81) with the corresponding tissue biopsies. Further, in a novel observation, we detected intra patient, inter-CTC heterogeneity of TMB and MSI, which has potential implications for immunotherapy response and development of resistance. Taken together, these data support the non-invasive biomarker interrogation and monitoring by liquid biopsy that incorporates CTC to complement tissue in informing treatment approaches. Citation Format: Andi K. Cani, Emily M. Dolce, Kevin Hu, Chia-Jen Liu, Elizabeth P. Darga, Dan Robinson, Yi-Mi Wu, Dafydd G. Thomas, Costanza Paoletti, Scott A. Tomlins, James M. Rae, Aaron M. Udager, Arul M. Chinnaiyan, Erin F. Cobain, Daniel F. Hayes. Serial monitoring of circulating tumor cells and circulating tumor DNA in metastatic lobular breast cancer identifies intra-tumor heterogeneity and precision and immuno-oncology biomarkers of therapeutic importance. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5595.
oncology
-
Circulating tumor cells and DNA as liquid biopsies
Ellen Heitzer,Martina Auer,Peter Ulz,Jochen B Geigl,Michael R Speicher
DOI: https://doi.org/10.1186/gm477
IF: 15.266
2013-08-01
Genome Medicine
Abstract:For cancer patients, the current approach to prognosis relies on clinicopathological staging, but usually this provides little information about the individual response to treatment. Therefore, there is a tremendous need for protein and genetic biomarkers with predictive and prognostic information. As biomarkers are identified, the serial monitoring of tumor genotypes, which are instable and prone to changes under selection pressure, is becoming increasingly possible. To this end, circulating tumor cells (CTCs) or circulating tumor DNA (ctDNA) shed from primary and metastatic cancers may allow the non-invasive analysis of the evolution of tumor genomes during treatment and disease progression through 'liquid biopsies'. Here we review recent progress in the identification of CTCs among thousands of other cells in the blood and new high-resolution approaches, including recent microfluidic platforms, for dissecting the genomes of CTCs and obtaining functional data. We also discuss new ctDNA-based approaches, which may become a powerful alternative to CTC analysis. Together, these approaches provide novel biological insights into the process of metastasis and may elucidate signaling pathways involved in cell invasiveness and metastatic competence. In medicine these liquid biopsies may emerge to be powerful predictive and prognostic biomarkers and could therefore be instrumental for areas such as precision or personalized medicine.
genetics & heredity
-
Abstract P4-02-04: Serial monitoring of circulating tumor cells and circulating tumor DNA in metastatic lobular breast cancer identifies intra-tumor heterogeneity and precision and immuno-oncology biomarkers of therapeutic importance
Andi Cani,Emily Dolce,Alissa Turnbull,Kevin Hu,Chia-Jen Liu,Elizabeth Darga,Dan Robinson,Yi-Mi Wu,Dafydd G. Thomas,Costanza Paoletti,Scott Tomlins,James Rae,Aaron Udager,Arul Chinnaiyan,Erin F. Cobain,Daniel F. Hayes
DOI: https://doi.org/10.1158/1538-7445.sabcs22-p4-02-04
IF: 11.2
2023-03-01
Cancer Research
Abstract:Abstract Clinical decisions on precision and immuno-oncology therapies are based on predictive biomarkers commonly obtained from a single metastatic biopsy or archived primary tumor tissue. Circulating genomic biomarkers offer a minimally invasive approach to monitor intra-patient tumor heterogeneity and detect in real-time the clinically-relevant evolving clonal architecture. Although currently underutilized, we hypothesize that single-cell DNA next generation sequencing (scNGS) of circulating tumor cells (CTC) is a particularly well-suited method to complement biomarker information obtained from tissue and cell-free circulating tumor DNA (ctDNA). In this study we analyzed 113 individual CTC, 21 ctDNA, and 15 white blood cells (WBC) samples, from 15 CTC-positive lobular breast cancer patients, four of whom had CTC available at both metastatic baseline and after progression on a variety of therapies chosen at their physician’s discretion. Clinical NGS data from 15 tumor tissue biopsies obtained using a ~1700-gene DNA panel and whole transcriptome sequencing were available for comparison. CTC were enriched with the CellSearch® system and isolated as single cells with the DEPArrayTM system. Whole genome amplified CTC and WBC, as well as ctDNA underwent scNGS with the Oncomine Comprehensive Assay covering ~500 genes and 1.1Mb of genomic space to detect mutations, copy number alterations, tumor mutation burden (TMB) and microsatellite instability (MSI). 99.1% of single cells and 95.2% of ctDNA samples were informative, with a mean sequencing depth of 664x. Using our previously developed, CTC-based precision medicine reporting platform, MI-CTCSeq, CTC in 9 of 15 patients (60%) had mutations that were actionable by FDA-approved targeted therapies including in the oncogenes PIK3CA and FGFR2 and HER2. 3 of these 9 patients (33%) harbored actionable alterations not shared between all 3 analyte types (tissue, CTC and ctDNA). These included 3 actionable mutations found in CTC and ctDNA only, 1 in tissue and ctDNA only, and 1 in ctDNA only. However, 2 of those ctDNA mutations were identified near the limit of detection and with a priori knowledge of their presence from tissue or CTC. Further, 1 patient with plentiful CTC had no detectable ctDNA and one patient’s tissue biopsy was inadequate for sequencing while both liquid biopsy analytes were abundant. 13 patients (87%) displayed intra-patient, inter-CTC genomic heterogeneity of putative driver mutations. 1 of 4 (25%) patients with CTC available in >1 timepoint displayed fluctuations in their CTC subclonal makeup between timepoints. Data from this patient’s 2 tissue biopsies, 3 ctDNA samples, and 27 individual CTC over 4 timepoints combined to reveal in unprecedented detail inter-metastatic lesion and inter-CTC heterogeneity and tumor evolution in response to endocrine and immunotherapy selective pressures. ScNGS of CTC helped provide an additional level of detail not appreciated by sequencing of the other two analyte types. In another patient, CTC were composed of 2 subclones which were indistinguishable by ctDNA, 1 of which appears to have not been sampled by the tissue biopsy. Using a novel method, we enabled detection of single-cell CTC TMB and MSI. CTC TMB scores (dichotomized as above/below 10 mutations/Mb) were 100% concordant with those measured in the corresponding tissue biopsies. Further, in a novel observation, we detected intra patient, inter-CTC heterogeneity of TMB and MSI, which has potential implications for immunotherapy response and development of resistance. Taken together, these data support the non-invasive biomarker interrogation and monitoring by liquid biopsy that incorporates CTC scNGS and complements tissue in informing precision and immuno-oncology approaches. This may have important implications for appropriate treatment selection and identification of therapeutic resistance mechanisms. Citation Format: Andi Cani, Emily Dolce, Alissa Turnbull, Kevin Hu, Chia-Jen Liu, Elizabeth Darga, Dan Robinson, Yi-Mi Wu, Dafydd G. Thomas, Costanza Paoletti, Scott Tomlins, James Rae, Aaron Udager, Arul Chinnaiyan, Erin F. Cobain, Daniel F. Hayes. Serial monitoring of circulating tumor cells and circulating tumor DNA in metastatic lobular breast cancer identifies intra-tumor heterogeneity and precision and immuno-oncology biomarkers of therapeutic importance [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P4-02-04.
oncology
-
Abstract 3498: A novel combination of tissue-informed, comprehensive genomic profiling (CGP) and non-bespoke blood-based profiling for quantifying circulating tumor DNA (ctDNA)
Terri Driessen,Christine Lo,Wei Zhu,Robert Tell,Jonathan Freaney,Halla Nimeiri,Kate Sasser
DOI: https://doi.org/10.1158/1538-7445.am2024-3498
IF: 11.2
2024-03-31
Cancer Research
Abstract:Background: Estimating quantitative circulating tumor fraction in liquid biopsy samples is a promising area of clinical development for monitoring therapeutic molecular response and correlates with patient outcomes. Here we introduce a sensitive measure of estimating ctDNA tumor fraction (ctDNA TF) using a novel combination of tissue-informed CGP with a non-bespoke, blood-based liquid biopsy panel. Methods: Advanced pan-solid tumor samples were sequenced with both the Tempus xF/xF+ (105/523 gene, liquid biopsy) and Tempus xT (648 genes, solid-tumor with matched buffy coat) NGS assays (samples collected within 90 days). A normal distribution was fit against the somatic variants detected in solid-tissue and variants with variant allele fractions (VAF) within two standard deviations were used as selected biomarkers in the corresponding liquid biopsy to calculate a tumor-informed ctDNA TF for each sample. Results: In the initial validation set (n=79 samples also sequenced with low-pass whole genome sequencing), the linearity of tumor-informed ctDNA TF was compared to mean VAF (R2=0.26, slope=0.55), ichorCNA (R2=0.84, slope=0.84), and tumor-naive ctDNA TF (R2=0.71, slope=0.90). In a larger validation set (n=12,080), 37.5% samples had no variants detected in both xF and/or xT. Of the remaining samples, the linearity of tumor-informed ctDNA TF was compared to mean VAF (R2=0.21, slope=0.55) and tumor-naive ctDNA TF (R2=0.65, slope=0.81). In a follow-up analysis, we required 5 or more variants be detected in both xF and xT (n=1,659 samples) and compared the linearity of tumor-informed ctDNA TF to mean VAF (R2=0.37, slope=0.64) and tumor-naive ctDNA TF (R2=0.68, slope=0.98). In samples that received xF+ profiling (n=567), 24.3% had no variants detected in both xF+ and xT. The linearity of tumor-informed ctDNA TF of the remaining samples was compared to mean VAF (R2=0.01, slope=0.26) and tumor-naive ctDNA TF (R2=0.63, slope=1.02). Increasing the required number of variants to 5 or more had marginal improvement in linearity of tumor-informed ctDNA TF to mean VAF (R2=0.12, slope=0.47) and tumor-naive ctDNA TF (R2=0.67, slope=1.13).The limit-of-blank of the tumor-informed ctDNA TF approach was established to be 0% in both xF and xF+, and the limit-of-detection was ≤0.1% demonstrating that tumor informed ctDNA TF is a sensitive measure in detecting tumor fraction at low concentration levels. Conclusion: Here we introduce a novel sensitive and specific tumor-informed, non-bespoke approach for estimating ctDNA TF. Linearity improves with increased panel size and increased variant number. These results suggest that a tumor-informed ctDNA TF can be utilized to improve the sensitivity of existing methods for estimating tumor fraction to help in treatment decisions using Tempus' tissue and liquid comprehensive NGS genomic profiling platform. Citation Format: Terri Driessen, Christine Lo, Wei Zhu, Robert Tell, Jonathan Freaney, Halla Nimeiri, Kate Sasser. A novel combination of tissue-informed, comprehensive genomic profiling (CGP) and non-bespoke blood-based profiling for quantifying circulating tumor DNA (ctDNA) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 3498.
oncology
-
Exploring Circulating Tumor DNA (CtDNA) and Its Role in Early Detection of Cancer: A Systematic Review
Parikshit Bittla,Simran Kaur,Vani Sojitra,Anam Zahra,Jhenelle Hutchinson,Oluwa Folawemi,Safeera Khan
DOI: https://doi.org/10.7759/cureus.45784
2023-09-22
Cureus
Abstract:There is a significant increase in the need for an efficient screening method that might identify cancer at an early stage and could improve patients' long-term survival due to the continued rise in cancer incidence and associated mortality. One such effort involved using circulating tumor DNA (ctDNA) as a rescue agent for a non-invasive blood test that may identify many tumors. A tumor marker called ctDNA is created by cells with the same DNA alterations. Due to its shorter half-life, it may be useful for both early cancer detection and real-time monitoring of tumor development, therapeutic response, and tumor outcomes. We obtained 156 papers from PUBMED using the MeSH approach in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) criteria and ten articles from additional online resources. After removing articles with irrelevant titles and screening the abstract and full text of the articles that contained information unrelated to or not specific to the title query using inclusion and exclusion criteria, 18 out of 166 articles were chosen for the quality check. Fourteen medium to high-quality papers were chosen out of the 18 publications to be included in the study design. The reviewed literature showed no significant utility of ctDNA in detecting early-stage tumors of size less than 1 cm diameter. Still, the ideal screening test would require the assay to detect a size <5 mm tumor, which is nearly impossible with the current data. The sensitivity and specificity of the assay ranged from 69% to 98% and 99%, respectively. Furthermore, CancerSEEK achieves tumor origin localization in 83% of cases, while targeted error correction sequencing (TEC-Seq) assays demonstrate a cancer detection rate ranging from 59% to 71%, depending on the type of cancer. However, it could be of great value as a prognostic indicator, and the levels are associated with progression-free survival (PFS) and overall survival (OS) rates, wherein the positive detection of ctDNA is associated with worse OS compared to the tumors detected through standard procedures, with an odds ratio (OS) of 4.83. We conclude that ctDNA could be better applied in cancer patients for prognosis, disease progression monitoring, and treatment outcomes compared to its use in early cancer detection. Due to its specific feature of recognizing the tumor-related mutations, it could be implemented as a supplemental tool to assess the nature of the tumor, grade, and size of the tumor and for predicting the outcomes by pre-operative and post-operative evaluation of the tumor marker, ctDNA, and thereby estimating PFS and OS depending on the level of marker present. A vast amount of research is required in early detection to determine the sensitivity, specificity, false positive rates, and false negative rates in evaluating its true potential as a screening tool. Even if the test could detect the mutations, an extensive workup for the search of tumor is required as the assay could only detect but cannot localize the disease. Establishing the clinical validity and utility of ctDNA is imperative for its implementation in future clinical practice.
English Else
-
Liquid biopsies come of age: towards implementation of circulating tumour DNA
Jonathan C. M. Wan,Charles Massie,Javier Garcia-Corbacho,Florent Mouliere,James D. Brenton,Carlos Caldas,Simon Pacey,Richard Baird,Nitzan Rosenfeld
DOI: https://doi.org/10.1038/nrc.2017.7
IF: 78.5
2017-02-24
Nature Reviews Cancer
Abstract:Key PointsCell-free DNA (cfDNA) is released predominantly by cell death into the bloodstream, although active secretion may have a role. Since the discovery of fetal cfDNA in the maternal circulation, cfDNA analysis has been rapidly implemented in clinical practice for noninvasive prenatal testing.Mutations were first detected in cfDNA more than two decades ago, and interest in circulating tumour DNA (ctDNA) as a noninvasive cancer diagnostic has increased considerably with the development of molecular methods that permit the sensitive detection and monitoring of multiple classes of mutation.ctDNA may have utility at almost every stage of the management of patients with cancer, including diagnosis, minimally invasive molecular profiling, treatment monitoring, the detection of residual disease and the identification of resistance mutations. ctDNA analysis may be broadly considered as a tool both for quantitative analysis of disease burden and for genomic analysis.The identification of ctDNA in individuals before a cancer diagnosis, and in presymptomatic individuals, suggests the possibility of ctDNA analysis as a tool for earlier detection and screening. Noninvasive cancer classification or subtyping has also emerged as a possibility, although for early detection, both technical and biological factors introduce challenges to the detection of mutant DNA in plasma and its interpretation.Monitoring multiple mutations in parallel can enhance the sensitivity of ctDNA detection, can be used to assess the clonal evolution of patients' disease and may identify resistance mutations before clinical progression is observed.ctDNA analysis is beginning to transition from the research setting into the clinic. The US Food and Drug Administration and the European Medicines Agency have approved ctDNA tests for specific indications in the absence of evaluable tumour tissue. Analysis of gene panels in plasma has now become available as a potential clinical tool. Large studies are under way to establish the overall performance and clinical utility of such assays when a tumour biopsy is not available for analysis.Potential applications of ctDNA have been demonstrated by a number of proof-of-principle studies. Prospective clinical trials are beginning to assess the clinical utility of ctDNA analysis for molecular profiling and disease monitoring. The increasing acceptance of ctDNA is enabling the field to move from exploratory ctDNA studies towards clinical trials in which ctDNA guides decision-making.In order to fully exploit the potential utility of liquid biopsies, it is essential that the biology of cfDNA and ctDNA is explored further. The mechanisms of release and degradation, and the factors that affect the representation of ctDNA in plasma, are poorly understood. The nature of ctDNA will be clarified through both large, well-annotated clinical studies and in vivo studies in which variables can be controlled.
oncology
-
Breast Cancer Circulating Tumor Cells: Current Clinical Applications and Future Prospects
Andi K Cani,Daniel F Hayes
DOI: https://doi.org/10.1093/clinchem/hvad191
IF: 12.114
2024-01-01
Clinical Chemistry
Abstract:Abstract Background Identification and characterization of circulating tumor markers, designated as “liquid biopsies,” have greatly impacted the care of cancer patients. Although more recently referring to circulating tumor DNA (ctDNA), the term liquid biopsy initially was coined to refer to any blood-borne biomarker related to malignancy, including circulating tumor cells (CTCs) in blood. In this manuscript, we review the specific state of the art of CTCs in breast cancer. Content Liquid biopsies might play a clinical role across the entire spectrum of breast cancer, from risk assessment, prevention, screening, and treatment. CTC counts have been shown to carry clear, independent prognostic information in the latter situation. However, the clinical utility of CTCs in breast cancer remains to be determined. Nonetheless, in addition to CTC enumeration, analyses of CTCs provide tumor molecular information representing the entire, often-heterogeneous disease, relatively noninvasively and longitudinally. Technological advances have allowed the interrogation of CTC-derived information, providing renewed hope for a clinical role in disease monitoring and precision oncology. Summary This narrative review examines CTCs, their clinical validity, and current prospects of clinical utility in breast cancer with the goal of improving patient outcomes.
medical laboratory technology
-
Abstract 2428: Novel ctDNA technology for early cancer detection by immunoprecipitation of tumor associated ctDNA fragments and analysis by qPCR
Jacob Micallef,Dorian Pamart,Jean-Valery V. Turatsinze,Thomas Bygott,Benjamin Berman,Brieuc Cuvelier,Marielle Herzog
DOI: https://doi.org/10.1158/1538-7445.am2024-2428
IF: 11.2
2024-03-23
Cancer Research
Abstract:Introduction: Current ctDNA methods involve extraction of all plasma cfDNA, next generation sequencing (NGS) and complex bioinformatic analysis. We have developed a novel ctDNA analysis in which classes of tumor derived ctDNA are isolated, with removal of all non-tumor cfDNA of the same sequences, for analysis by qPCR. We now report the results of this analysis on cohorts of patients diagnosed with common solid cancers. Methods: We developed a chromatin immunoprecipitation (ChIP)/qPCR method for the isolation of cell free plasma CTCF-DNA (cfCTCF-DNA) nucleoproteins that include binding sites selectively occupied in cancer. CfDNA fragments of non-cancer origin that comprise the same CTCF binding site sequences are nucleosome covered and washed away. We performed plasma CTCF ChIP-Seq discovery experiments to identify CTCF gain of occupancy cancer biomarker sequences by analysis of plasma samples taken from cancer patients as well as patients with inflammatory conditions and healthy volunteers. Suitable pan-cancer, or cancer tissue specific, biomarkers were selected as characterized CTCF binding site sequences that were present in the ChIP isolates of cancer patients but absent in isolates from patients without cancer. We then developed qPCR assays for selected CTCF gain of occupancy biomarker sequences. We initially investigated whether CTCF gain of occupancy biomarkers would identify patients with cancer in a small cohort of subjects with acute myeloid leukemia (AML) (n=31), breast (n=10), prostate (n=10), liver (n=10) or colorectal cancer (CRC) (n=13) and 50 control subjects including 15 subjects with an inflammatory condition. Results: In our small initial experiments, a simple cutoff where a qPCR result exceeding the cutoff was positive, a single qPCR assay detected 19 of 31 AML cases (61%) with 1 false positive result among 50 control samples (98% specificity). Addition of a second qPCR assay to make a 2-member qPCR panel, where a result exceeding cutoff in either or both assays was classified as positive, resulted in the detection of 23 of 31 AML cases (74%) with 2 false positive results (96% specificity). On the same basis a 2-member qPCR panel also detected 58% of solid cancers including 44% of stage I cases. Another 2-member qPCR panel detected 77% of CRC cases at 92% specificity. We now report the results of investigations of larger cohorts of patients with common solid cancers by cancer type, stage and tissue specificity. Conclusion: Combining the isolation of plasma cfCTCF-DNA nucleoproteins with PCR analysis of cancer associated CTCF gain of occupancy binding site sequences is a novel ctDNA analysis technology that may provide the basis of useful, rapid, low cost, automated liquid biopsy methods. Further clinical studies to ascertain the clinical accuracy of the method are required. Citation Format: Jacob Micallef, Dorian Pamart, Jean-Valery V. Turatsinze, Thomas Bygott, Benjamin Berman, Brieuc Cuvelier, Marielle Herzog. Novel ctDNA technology for early cancer detection by immunoprecipitation of tumor associated ctDNA fragments and analysis by qPCR [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 2428.
oncology
-
Circulating tumor DNA by high-throughput sequencing of T cell receptor monitored treatment response and predicted treatment failure in T cell lymphomas
Wei Zhang,Wei Wang,Xiao Han,Yulai Gan,Long Qian,Yan Zhang,Chunliu Zhang,Yuqi Wang,Yanfang Guan,Ling Yang,Daobin Zhou
DOI: https://doi.org/10.1111/ijlh.13498
Abstract:Introduction: Next-generation sequencing (NGS)-based circulating tumor DNA (ctDNA) detection is a promising monitoring tool for lymphoid malignancies. Studies for T cell lymphoma are limited. Methods: We explored whether this technology is applicable to T cell lymphoma with different subtypes and assessed its performance in clinical settings. Results: Thirty tumor and 74 blood samples were analyzed in our study. Malignant clone was identified in 23 of the 30 (76.7%) tumor samples through high-throughput sequencing (HTS) combined with PCR. We detected the same tumor clone in plasma in 18out of the 23 (78.3%) patients. Circulating tumor DNA fraction correlated with lactate dehydrogenase (LDH) (r = .52, P = .017), high level of ctDNA predicted treatment failure (P = .0003) and there was a trend patients with high ctDNA burden would have poorer PFS Furthermore, ctDNA changed in concordance with clinical outcome and was more sensitive than PET/CT. Also, recurrence of ctDNA was an important clue for relapse. Conclusion: In conclusion, our study indicated that ctDNA monitoring was suitable for T cell lymphoma. High level of pretreatment ctDNA was a poor prognosis factor and changes of ctDNA correlated well with clinical courses and was sensitive to find early relapse.
-
Circulating tumor DNA in cancer diagnosis, monitoring, and prognosis
Sudeepto Saha,Yusha Araf,Salman Khan Promon
DOI: https://doi.org/10.1186/s43046-022-00109-4
2022-02-21
Journal of the Egyptian National Cancer Institute
Abstract:Abstract Background Circulating tumor DNA (ctDNA) has become one of the crucial components for cancer detection with the increase of precision medicine practice. ctDNA has great potential as a blood-based biomarker for the detection and treatment of cancer in its early stages. The purpose of this article was to discuss ctDNA and how it can be utilized to detect cancer. The benefits and drawbacks of this cancer detection technology, as well as the field’s future possibilities in various cancer management scenarios, are discussed. Main text ctDNA has clinical applications in disease diagnosis and monitoring. It can be used to identify mutations of interest and genetic heterogeneity. Another use of ctDNA is to monitor the effects of therapy by detecting mutation-driven resistance. Different technologies are being used for the detection of ctDNA. Next-generation sequencing, digital PCR, real-time PCR, and mass spectrometry are used. Using dPCR makes it possible to partition and analyze individual target sequences from a complex mixture. Mass-spectrometry technology enables accurate detection and quantification of ctDNA mutations at low frequency. Surface-enhanced Raman spectroscopy (SERS) and UltraSEEK are two systems based on this technology. There is no unified standard for detecting ctDNA as it exists in a low concentration in blood. As there is no defined approach, false positives occur in several methods due to inadequate sensitivities. Techniques used in ctDNA are costly and there is a limitation in clinical settings. Short conclusion A detailed investigation is urgently needed to increase the test's accuracy and sensitivity. To find a standard marker for all forms of cancer DNA, more study is needed. Low concentrations of ctDNA in a sample require improved technology to provide the precision that low concentrations of ctDNA in a sample afford.
-
Abstract ED06-03: Circulating tumor cells versus circulating tumor cell products
Klaus Pantel
DOI: https://doi.org/10.1158/1940-6215.prev-13-ed06-03
2013-11-01
Abstract:Abstract Metastasis is the main cause of cancer-related death and prevention of metastatic relapse is, therefore, the most important goal of cancer therapy. Distant metastases harbour unique genomic characteristics not detectable in the corresponding primary tumor of the same patient and metastases located at different sites show a considerable intra-patient heterogeneity. Thus, the mere analysis of the resected primary tumor alone (current standard practise in oncology) or, if possible, even re-evaluation of tumor characteristics based on the biopsy of the most accessible metastasis may not reveal sufficient information for treatment decisions. This dilemma can be solved by a new diagnostic concept: Liquid biopsy, i.e., analysis of therapeutic targets and drug resistance-conferring gene mutations on circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA) released into the peripheral blood from metastatic deposits. In addition, cell-free microRNAs in the peripheral blood of cancer patients may provide real-time insights into the biology of cancer, including the effects of therapeutic interventions. MicroRNA levels in plasma, serum, urine and other body fluids have been used to detect cancer, predict the prognosis and response to therapy. Here the current challenges and future perspectives of CTCs and circulating nucleic acids as biomarkers in clinical oncology will be discussed. Both CTCs and circulating nucleic acids are interesting complementary technologies that can be used in parallel in future trials assessing new drugs or drug combinations. We postulate that the liquid biopsy concept will contribute to a better understanding and prevention of metastatic relapse and progression in cancer patients. Citation Format: Klaus Pantel. Circulating tumor cells versus circulating tumor cell products. [abstract]. In: Proceedings of the Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2013 Oct 27-30; National Harbor, MD. Philadelphia (PA): AACR; Can Prev Res 2013;6(11 Suppl): Abstract nr ED06-03.
-
Circulating tumor DNA (ctDNA) as a pan-cancer screening test: is it finally on the horizon?
Michael J. Duffy,Eleftherios P. Diamandis,John Crown
DOI: https://doi.org/10.1515/cclm-2021-0171
2021-04-14
Clinical Chemistry and Laboratory Medicine (CCLM)
Abstract:Abstract The detection of cancer at an early stage while it is curable by surgical resection is widely believed to be one of the most effective strategies for reducing cancer mortality. Hence, the intense interests in the development of a simple pan-cancer screening test. Lack of sensitivity and specificity when combined with the low prevalence of most types of cancer types in the general population limit the use of most of the existing protein biomarkers for this purpose. Like proteins, tumor DNA also can be released into the circulation. Such circulating tumor DNA (ctDNA) can be differentiated from normal cell DNA by the presence of specific genetic alteration such as mutations, copy number changes, altered methylation patterns or being present in different sized fragments. Emerging results with test such as CancerSEEK or GRAIL suggest that the use of ctDNA can detect cancer with specificities >99%. Sensitivity however, is cancer type and stage-dependent, varying from approximately 40% in stage I disease to approximately 80% in stage III disease. It is important to stress however, that most of the studies published to date have used patients with an established diagnosis of cancer while the control population were healthy individuals. Although the emerging results are promising, evidence of clinical utility will require demonstration of reduced mortality following evaluation in a prospective randomized screening trial.
-
Classifying circulating tumor cells to monitor cancer progression
Panagiota Economopoulou,Vassilis Georgoulias,Athanasios Kotsakis
DOI: https://doi.org/10.1080/14737159.2017.1275572
2016-12-29
Expert Review of Molecular Diagnostics
Abstract:INTRODUCTION: The term 'liquid biopsy' refers to molecular analysis of a tumor's genetic features based on circulating genetic material in the peripheral blood derived from circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) and circulating miRNAs, and has emerged as a minimally invasive tool in early cancer diagnosis and disease monitoring. CTCs are believed to originate from the primary tumor and obtain genetic heterogeneity during evolution. Areas covered: The presence of CTCs has been associated with poor clinical outcome in patients with metastatic breast cancer, lung cancer, colorectal cancer and prostate cancer. In addition, the detection of CTCs in patients with early breast cancer has been shown to represent an independent prognostic factor associated with an unfavorable clinical outcome. Moreover, the longitudinal evaluation of CTCs in patients with early breast cancer may reveal the presence of chemo- and hormone-therapy resistant CTCs which are associated with an increased risk for disease relapse and disease-related death. Expert commentary: The molecular characterization of CTCs may provide an important tool for the monitoring and the evaluation of treatment efficacy in patients with different tumor types such as breast, prostate, colon, and non-small cell lung cancer.
pathology
-
Abstract 1700: Serial monitoring of single-cell circulating tumor cell genomics in metastatic lobular breast cancer to identify precision and immuno-oncology biomarkers with therapeutic implications
Andi K. Cani,Emily M. Dolce,Elizabeth P. Darga,Kevin Hu,Chia-Jen Liu,James M. Rae,Daffyd G. Thomas,Scott A. Tomlins,Arul M. Chinnaiyan,Aaron M. Udager,Costanza Paoletti,Erin F. Cobain,Daniel F. Hayes
DOI: https://doi.org/10.1158/1538-7445.am2022-1700
IF: 11.2
2022-06-17
Cancer Research
Abstract:Clinical decisions for precision and immuno-oncology therapies are based on predictive biomarkers commonly obtained from a single metastatic biopsy, or from archived primary tumor material. Circulating genomic biomarkers present a minimally invasive way to monitor the intra-patient tumor heterogeneity and its fluctuations in order to provide a real-time evaluation of the changing clonal architecture with potential therapeutic implications. Single-cell DNA next generation sequencing (scNGS) of circulating tumor cells (CTC) is a particularly well-suited method of unraveling and monitoring that heterogeneity to complement biomarker information obtained from tissue and cell-free circulating tumor DNA (ctDNA). In this proof-of-concept study we analyzed 123 CTC, 15 white blood cells (WBC), and ctDNA from 15 CTC-positive lobular breast cancer patients, five of whom had CTC available at both metastatic baseline and after progression on a variety of therapies chosen at their physician's discretion. CTC were enriched with the CellSearch® system and isolated as single cells with the DEPArrayTM system. Whole genome amplified CTC DNA underwent scNGS with the Oncomine Comprehensive Assay covering ~500 genes and 1.1Mb of genomic space to detect mutations, copy number alterations, tumor mutation burden (TMB) and microsatellite instability (MSI). 99.1% of cells were informative, with a mean sequencing depth of 664x. Using our previously developed, CTC-based precision medicine reporting platform, MI-CTCSeq, multiple CTC in seven of 15 patients (47%) had mutations that were actionable by FDA-approved targeted therapies including in the oncogenes PIK3CA (alpelisib) and FGFR2 (erdafitinib). 13 patients (87%) displayed intra-patient, inter-CTC genomic heterogeneity of putative driver mutations. Two of five (40%) patients with CTC at both baseline and progression displayed fluctuations in their CTC subclonal makeup between timepoints. One of the two harbored a baseline ESR1 (estrogen receptor α) p.D538G activating mutation that largely disappeared at progression and was replaced by a CTC subclone with a different ESR1 activating mutation, p.Y537S. Intriguingly, this patient's CTC also harbored an FGFR2 p.K659M mutation in an actionable "hotspot" at progression, which was absent at baseline, suggesting potential utility of serial monitoring by CTC scNGS. TMB scores and MSI status in CTC were highly concordant with those measured in clinical tissue biopsies. Taken together, these data suggest the non-invasive interrogation of the CTC genomic landscape and its serial monitoring to inform precision and immuno-oncology treatments in real time. Citation Format: Andi K. Cani, Emily M. Dolce, Elizabeth P. Darga, Kevin Hu, Chia-Jen Liu, James M. Rae, Daffyd G. Thomas, Scott A. Tomlins, Arul M. Chinnaiyan, Aaron M. Udager, Costanza Paoletti, Erin F. Cobain, Daniel F. Hayes. Serial monitoring of single-cell circulating tumor cell genomics in metastatic lobular breast cancer to identify precision and immuno-oncology biomarkers with therapeutic implications [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 1700.
oncology
-
Abstract 5380: an Integrated Platform for the Clinical Detection and Molecular Profiling of Single Circulating Tumor Cells
Pengxiang Wang,Yunfan Sun,Weixiang Jin,Haixiang Peng,Jian Zhou,Jia Fan,Xinrong Yang
DOI: https://doi.org/10.1158/1538-7445.am2020-5380
IF: 11.2
2020-01-01
Cancer Research
Abstract:Abstract Introduction: Detection of circulating tumor cells (CTCs) and characterization of CTCs at single-cell resolution may benefit the clinical management of cancer patients. To make the CTC analysis a “bench-to-bedside” technology, we developed an integrated platform named ChimeraX®-i120 system for the high-throughput, automated, and clinical applicable CTC sorting and downstream single-cell genomic profiling. Methods: ChimeraX®-i120 system is designed based on negative enrichment strategy, integrating blood sample pre-processing, immunofluorescence staining, artificial intelligence (AI)-assisted CTC identification. CTCs enriched by this system is compatible with downstream single-cell whole genome sequencing (WGS) analysis. Performance of CTCs detection was evaluated by a series of analytical experiments, clinical utility was further verified. We validated our downstream molecular profiling pipeline of single CTC. Results: Analytical experiments showed that this system was featured with high accuracy, repeatability, sensitivity and anti-interference capability for CTC detection, achieving an average recovery rate of the spiked cells in 71.3%-83.2% (R2= 0.99). In clinical samples, this system effectively detected CTCs and CTC clusters (CTM) in 5 mL blood from cancer patients. The proportion of patients that were positive for CTCs (EpCAM+/pan-CK++CD45-+DAPI+), was 59.3% (86/145, avg. cell count 1.38 ± 2.01) for hepatocellular carcinoma (HCC), 63.2% (24/38, 1.42 ± 1.75) for intrahepatic cholangiocarcinoma (ICC), 63.6% (28/44, avg. 2.52 ± 3.93) for breast cancer (BRC), 61.5% (24/39, avg. 1.62 ± 2.11) in colorectal cancer (CRC), 78.9% (15/19, avg. 2.74 ± 4.46) in lung cancer (LC). Only 1 of 125 (0.8%) healthy volunteers had detectable CTC. The prognostic value of the system was assessed in HCC. Preoperative CTC ≥1/5mL blood was significantly associated with a higher 1-year recurrence rate (38.9% vs. 27.6%, P=0.042) in HCC patients after curative surgery. Low-pass WGS analysis was performed on CTCs and paired tumor tissues of 3 ICC, 3 HCC and 4 BRC. We observed concordance in CNAs (10%-61%) between CTCs and tissues. CTC profiling identified diverse intra- and inter-patient heterogeneity in CNAs pattern. Exclusive CNA patterns were identified in CTCs but not tissue, and vice versa. Multiple well-known oncogenes (e.g., BRAF, EGFR, BRCA1/2, MYC and MET) and tumor suppressor genes (e.g., FOXA1 and TRAF3) could be identified from CNAs in CTCs. For example, in one BRC patient, potentially actionable alterations of BRC such as BRAF, EGFR, MET, ERBB2, PIK3CA and MYC were only identified in CTCs but not tissues. Conclusion: Our results highlight the potential clinical utility of ChimeraX®-i120 system in both CTC detection and downstream genomic profiling. Genomic sequencing of CTCs allows blood-based tumor profiling in greater fraction of patients for clinical decision making. Citation Format: Pengxiang Wang, Yunfan Sun, Weixiang Jin, Haixiang Peng, Jian Zhou, Jia Fan, Xinrong Yang. An integrated platform for the clinical detection and molecular profiling of single circulating tumor cells [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 5380.
-
Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening
Jacob J. Adashek,Filip Janku,Razelle Kurzrock
DOI: https://doi.org/10.3390/cancers13143600
2021-07-18
Cancers
Abstract:With the addition of molecular testing to the oncologist’s diagnostic toolbox, patients have benefitted from the successes of gene- and immune-directed therapies. These therapies are often most effective when administered to the subset of malignancies harboring the target identified by molecular testing. An important advance in the application of molecular testing is the liquid biopsy, wherein circulating tumor DNA (ctDNA) is analyzed for point mutations, copy number alterations, and amplifications by polymerase chain reaction (PCR) and/or next-generation sequencing (NGS). The advantages of evaluating ctDNA over tissue DNA include (i) ctDNA requires only a tube of blood, rather than an invasive biopsy, (ii) ctDNA can plausibly reflect DNA shedding from multiple metastatic sites while tissue DNA reflects only the piece of tissue biopsied, and (iii) dynamic changes in ctDNA during therapy can be easily followed with repeat blood draws. Tissue biopsies allow comprehensive assessment of DNA, RNA, and protein expression in the tumor and its microenvironment as well as functional assays; however, tumor tissue acquisition is costly with a risk of complications. Herein, we review the ways in which ctDNA assessment can be leveraged to understand the dynamic changes of molecular landscape in cancers.
oncology
-
Circulating tumor cells et al.: towards a comprehensive liquid biopsy approach in breast cancer
Eleonora Nicolò,Caterina Gianni,Letizia Pontolillo,Mara Serena Serafini,Laura Sofia Munoz-Arcos,Eleni Andreopoulou,Giuseppe Curigliano,Carolina Reduzzi,Massimo Cristofanilli
DOI: https://doi.org/10.21037/tbcr-23-55
2024-04-26
Abstract:Liquid biopsy has emerged as a crucial tool in managing breast cancer (BC) patients, offering a minimally invasive approach to detect circulating tumor biomarkers. Until recently, the majority of the studies in BC focused on evaluating a single liquid biopsy analyte, primarily circulating tumor DNA and circulating tumor cells (CTCs). Despite the proven prognostic and predictive value of CTCs, their low abundance when detected using enrichment methods, especially in the early stages, poses a significant challenge. It is becoming evident that combining diverse circulating biomarkers, each representing different facets of tumor biology, has the potential to enhance the management of patients with BC. This article emphasizes the importance of considering these biomarkers as complementary/synergistic rather than competitive, recognizing their ability to contribute to a comprehensive disease profile. The review provides an overview of the clinical significance of simultaneously analyzing CTCs and other biomarkers, including cell-free circulating DNA, extracellular vesicles, non-canonical CTCs, cell-free RNAs, and non-malignant cells. Such a comprehensive liquid biopsy approach holds promise not only in BC but also in other cancer types, offering opportunities for early detection, prognostication, and therapy monitoring. However, addressing associated challenges, such as refining detection methods and establishing standardized protocols, is crucial for realizing the full potential of liquid biopsy in transforming our understanding and approach to BC. As the field evolves, collaborative efforts will be instrumental in unlocking the revolutionary impact of liquid biopsy in BC research and management.
-
Application of Circulating Tumor DNA As a Biomarker for Non-Small Cell Lung Cancer
Jialiang Yang,Yan Hui,Yanxiang Zhang,Minghui Zhang,Binbin Ji,Geng Tian,Yangqiang Guo,Min Tang,Lianxing Li,Bella Guo,Tonghui Ma
DOI: https://doi.org/10.3389/fonc.2021.725938
IF: 4.7
2021-01-01
Frontiers in Oncology
Abstract:Background Non-small cell lung cancer (NSCLC) is one of the most prevalent causes of cancer-related death worldwide. Recently, there are many important medical advancements on NSCLC, such as therapies based on tyrosine kinase inhibitors and immune checkpoint inhibitors. Most of these therapies require tumor molecular testing for selecting patients who would benefit most from them. As invasive biopsy is highly risky, NSCLC molecular testing based on liquid biopsy has received more and more attention recently. Objective We aimed to introduce liquid biopsy and its potential clinical applications in NSCLC patients, including cancer diagnosis, treatment plan prioritization, minimal residual disease detection, and dynamic monitoring on the response to cancer treatment. Method We reviewed recent studies on circulating tumor DNA (ctDNA) testing, which is a minimally invasive approach to identify the presence of tumor-related mutations. In addition, we evaluated potential clinical applications of ctDNA as blood biomarkers for advanced NSCLC patients. Results Most studies have indicated that ctDNA testing is critical in diagnosing NSCLC, predicting clinical outcomes, monitoring response to targeted therapies and immunotherapies, and detecting cancer recurrence. Moreover, the changes of ctDNA levels are associated with tumor mutation burden and cancer progression. Conclusion The ctDNA testing is promising in guiding the therapies on NSCLC patients.
-
Cell‐free DNA‐associated Multi‐feature Applications in Cancer Diagnosis and Treatment
Xiaolu Zhang,Jingwei Li,Xun Lan,Jie Li
DOI: https://doi.org/10.1002/ctd2.280
2024-01-01
Clinical and Translational Discovery
Abstract:AbstractMalignant tumours pose significant challenges in terms of high morbidity and mortality rates, primarily due to the lack of large‐scale applicable screening methods and efficient treatment strategies. However, the development of liquid biopsies, particularly circulating cell‐free DNA (cfDNA), offers promising solutions characterised by their non‐invasiveness and cost‐effectiveness, providing comprehensive tumour information on a global scale. The release of cfDNA is predominantly associated with cell death and turnover, while its elimination occurs through nuclease digestion, renal excretion into the urine and uptake by the liver and spleen. Extensive research into the biological properties of cfDNA has led to the identification of novel applications, including non‐invasive cancer screening, cancer subtype classification, tissue‐of‐origin detection and monitoring of treatment efficacy. Additionally, emerging fields such as methylation‐omics, fragment‐omics and nucleosome‐omics show immense potential as tissue‐ and disease‐specific markers. Therefore, this review aims to comprehensively introduce the latest detection techniques of cfDNA, along with detailed information on its characteristics and applications, providing valuable insights for cancer diagnosis and monitoring, which will assist us in purposefully enhancing relevant features for a more comprehensive application in clinical practice.